Alnara Pharmaceuticals makes appointment

Alnara Pharmaceuticals, a US company developing non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, has appointed Dr Lee Brettman to the newly created position of chief medical officer. He has almost 20 years' pharmaceutical industry leadership experience; before joining Alnara, Dr Brettman was the founder, president and CEO of Dynogen Pharmaceuticals. He has also worked at Oxford Bioscience Partners and Millennium Pharmaceuticals.

Alnara Pharmaceuticals, a US company developing non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, has appointed Dr Lee Brettman to the newly created position of chief medical officer. He has almost 20 years' pharmaceutical industry leadership experience; before joining Alnara, Dr Brettman was the founder, president and CEO of Dynogen Pharmaceuticals. He has also worked at Oxford Bioscience Partners and Millennium Pharmaceuticals.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By 

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

More from Scrip